After months of searching for a new partner to market its bone cancer therapeutic agent Quadramet, radiopharmaceutical firm Cytogen of Princeton, NJ, announced Oct. 29 that it had signed an exclusive license agreement with Berlex Laboratories for the
After months of searching for a new partner to market its bone cancer therapeutic agent Quadramet, radiopharmaceutical firm Cytogen of Princeton, NJ, announced Oct. 29 that it had signed an exclusive license agreement with Berlex Laboratories for the manufacture and sale of the product. The deal covers marketing and sales in North and South America, and the two companies are in the process of securing a long-term supply agreement with Du Pont Pharmaceutical of North Billerica, MA, Cytogens former marketing partner and current contract manufacturer of Quadramet.
Berlex will pay Cytogen $8 million when the supply agreement with Du Pont is finalized. Cytogen will pay half of the money to Du Pont to establish a five-year manufacturing deal. Berlex will also pay royalties to Cytogen on net sales of Quadramet, as well as milestone payments for achieving predetermined sales levels. The Montville, NJ, company expects to begin marketing Quadramet in January 1999. Cytogen plans to conclude phase IV post-approval studies required by the Food and Drug Administration in its clearance of Quadramet.
The Berlex deal closes an interim agreement between Cytogen and Du Pont, in which Du Pont agreed to identify marketing partner candidates for Cytogen (SCAN 10/28/98).
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.